BioSpace News Archive

FEI Systems, a Columbia, Maryland-based provider of health information technology solutions, was awarded a contract from the Florida Department of Children and Families (DCF) in support of the State’s opioid response initiatives and the State Opioid Response Grant, awarded by SAMHSA.

Kymera Therapeutics Inc., a biotechnology company pioneering targeted protein degradation to create breakthrough medicines for patients, will present new preclinical data for its first-in-class oral IRAK4 protein degrader, KYM-001, in MYD88-mutant lymphoma

Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 therapies for cancer, today announced the presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting to be held March 29 – April 3, 2019 in Atlanta, GA.

CUBEX LLC’s MedBank™ Medical Solutions announced that Community Pharmacy, a long-term care pharmacy prominent throughout the Midwest, will expand their emergency medication access with the MedBank Mini product line.

Black Diamond Therapeutics, Inc. announced that data from its first-in-class program targeting a group of epidermal growth factor receptor allosteric mutants that drive glioblastoma multiforme will be presented at the American Association for Cancer Research Annual Meeting 2019.

Foresee Pharmaceuticals Co., Ltd. (6576.TWO) (“Foresee”), announced today that it has submitted to the U.S. Food and Drug Administration a 505(b)(2) New Drug Application for LMIS 50 mg, a ready-to-use 6-month depot formulation of leuprolide mesylate.

Wolf Popper LLP announced that it has filed a securities class action lawsuit in the United States District Court for the Middle District of Florida against First Choice Healthcare Solutions, Inc. and its former Chairman, CEO, and President Christian Romandetti, Sr.

The American Diabetes Association’s Chief Scientific, Medical and Mission Officer, William T. Cefalu, MD, will testify before the U.S. House of Representatives Committee on Energy & Commerce’s Oversight and Investigations Subcommittee

GENFIT SA (Euronext: GNFT – ISIN: FR0004163111) (“GENFIT” or the “Company”), a French biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, today announced the closing of its previously announced global offering to specified categories of investors of an aggregate of 7,647,500 new ordinary shares

Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III study comparing surufatinib (HMPL-012 or sulfatinib) with capecitabine in patients with advanced biliary tract cancer (“BTC”) whose disease progressed on first-line chemotherapy.